NCT05103345View on ClinicalTrials.gov

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

SGN1

SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.

Trial Locations (4)

23561

RECRUITING

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, New Taipei City

511495

RECRUITING

Guangdong Clifford Hospital, Guangzhou

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

Unknown

RECRUITING

China Medical University Hospital, Taichung

Sponsors

Collaborators (1)

Pharmaron
All Listed Sponsors
collaborator

Pharmaron

INDUSTRY

lead

Guangzhou Sinogen Pharmaceutical Co., Ltd

OTHER

NCT05103345 - Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Biotech Hunter | Biotech Hunter